Previous 10 | Next 10 |
In an interview with CNBC, Health Secretary Alex Azar revealed that the Trump administration is working on a plan that would allow the U.S. to import medicines from Canada, but offered no additional details as to how the plan would work. More news on: ProShares Trust - ProShares Ultra Na...
By a 19-9 vote, the Prescription Drug Pricing Reduction Act has advanced out of the Senate Finance Committee and will go before the full Senate this fall. The bill would cap out-of-pocket costs for medicines at $3,100 per year for Medicare beneficiaries beginning in 2022 and require drug m...
U.S. Senator Jeanne Shaheen (D-NH) has introduced a bipartisan bill , the Insulin Price Reduction Act, that she says will rein in skyrocketing costs of insulin while holding pharmacy benefit managers to account for their role in surging prices, adding that the cost of the most popular insul...
Major drug makers are under water nearing the close as skittish investors move the sidelines ahead of President Trump's plan to peg Medicare reimbursement to the lowest ex-U.S. prices from a select group of countries. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Heal...
Biotechs and biopharma players are modestly in the green after a D.C. district court stopped a Trump administration initiative requiring drug makers to disclose list prices in television advertisements. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & ...
Biopharma and biotech players are mostly in the red (again) ahead of an expected executive order from President Trump aimed at corralling U.S. drug prices. Specifically, the order will contain a "favored nation" clause that will be the basis for Medicare reimbursement, i.e., the reimbursem...
ETFs have become a dominant force in the market. Here are the winners and losers so far this year. Winning ETFs 2019 First Half It should not come as a surprise that one of the most volatile of all asset classes - bitcoin - is the top-performing ETF this year. Bitcoin aficionados...
Investing in biotechnology companies can be a long road to make gains given the volatility of the sector; even with a good understanding of the system, no one can predict what treatment, device, or therapy will give investors the biggest return, which makes biotechnology ETFs (exchange tra...
Early July is typically one of the two times each calendar year that U.S. drugmakers hike prices. Yesterday, on cue, many appeared to do just that . More news on: GlaxoSmithKline plc, Amneal Pharmaceuticals, Inc., ProShares Ultra Nasdaq Biotechnology ETF, Healthcare stocks news, Stocks on...
Gainers: Natural Gas 3X Long ETN Velocityshares (NYSEARCA: UGAZ ) +19.4% . Ultra DJ-UBS Natural Gas Proshares (NYSEARCA: BOIL ) +13.0% . Semiconductor Bull 3X Direxion (NYSEARCA: SOXL ) +10.6% . Ipatha.B Coffee Subindex TR ETN (NYSEARCA: JO ) +9.3% . Direxion ...
News, Short Squeeze, Breakout and More Instantly...
ARK Genomic Revolution ETF Company Name:
ARKG Stock Symbol:
NYSE Market:
2024-06-26 11:19:20 ET Shares of Ginkgo Bioworks (NYSE: DNA) were sinking 8.3% lower as of 11:03 a.m. ET on Wednesday. The decline continued after the stock fell nearly 11% on Tuesday following two negative developments for Ginkgo. Following the market close on Monday, the biote...
2024-05-15 11:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-22 05:43:00 ET Cathie Wood, a well-known fund manager who heads asset management company Ark Invest, is known for her ultra-aggressive investing style, which targets breakout themes and paradigm-shifting technologies. Despite a strong performance by many broader benchmarks this ...